[Efficacy of treatment with high-dose toremifene in patients with metastatic breast cancer resistant to aromatase inhibitor treatment].
The efficacy of aromatase inhibitors(AI)has been established for adjuvant and metastatic breast cancer. However, decision making regarding treatment becomes difficult after AI treatment. Recently, high-dose toremifene(HD-TOR, TOR 120 mg daily)showed efficacy in these patients. We attempted to study retrospectively the efficacy and safety of HD-TOR treatment. Seven patients received HD-TOR. The overall response rate was 29%(PR 2)and clinical benefit (CR, PR, long SD)was 57%(PR 2, long SD 7). HD-TOR may be an optional treatment for MBC after AI treatment.
Niikura
Naoki
N
Dept. of Surgery, Sougo Oota Hospital, Japan.
Kimura
Morihiko
M
Kobayashi
Youichi
Y
Asahara
Fumitaka
F
Hayashi
Kouji
K
Shibata
Sansei
S
Shintoku
Junichi
J
D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008875:Middle Aged; D012189:Retrospective Studies; D017312:Toremifene / Q000008:administration & dosage*
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D017312:Toremifene